Company intelligence / Profile preview
Fundamenta Therapeutics Inc.
Suzhou, Jiangsu Sheng, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Preliminary analyses show promising activity of their non-gene-editing allogenic CAR-T therapies in relapsed/refractory Non-Hodgkin’s lymphoma and other hematologic malignancies. The lead candidate ThisCART19A is currently in Phase I for autoimmune hemolytic anemia with a high likelihood of phase transition success based on historical benchmarks
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapies (including Universal CAR-T)TCR therapyMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Fundamenta Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fundamenta Therapeutics Inc..